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ABSTRACT
Purpose: Expression profiling studies classified breast
carcinomas into estrogen receptor (ER)/luminal, normal
breast-like, HER2 overexpressing, and basal-like groups,
with the latter two associated with poor outcomes. Cur-
rently, there exist clinical assays that identify ER/luminal
and HER2-overexpressing tumors, and we sought to develop
a clinical assay for breast basal-like tumors.
Experimental Design: To identify an immunohistochem-
ical profile for breast basal-like tumors, we collected a series
of known basal-like tumors and tested them for protein
patterns that are characteristic of this subtype. Next, we
examined the significance of these protein patterns using
tissue microarrays and evaluated the prognostic significance
of these findings.
Results: Using a panel of 21 basal-like tumors, which
was determined using gene expression profiles, we saw that
this subtype was typically immunohistochemically negative
for estrogen receptor and HER2 but positive for basal cy-
tokeratins, HER1, and/or c-KIT. Using breast carcinoma
tissue microarrays representing 930 patients with 17.4-year
mean follow-up, basal cytokeratin expression was associated
with low disease-specific survival. HER1 expression was
observed in 54% of cases positive for basal cytokeratins
(versus 11% of negative cases) and was associated with poor
survival independent of nodal status and size. c-KIT expres-
sion was more common in basal-like tumors than in other
breast cancers but did not influence prognosis.
Conclusions: A panel of four antibodies (ER, HER1,
HER2, and cytokeratin 5/6) can accurately identify basal-
like tumors using standard available clinical tools and shows
high specificity. These studies show that many basal-like
tumors express HER1, which suggests candidate drugs for
evaluation in these patients.
INTRODUCTION
Recent DNA microarray profiling studies on breast tumors
have identified distinct subtypes of breast carcinomas that are
associated with different clinical outcomes (1, 2). Using an
intrinsic set of 534 genes, Sørlie et al. (2) analyzed the expres-
sion profiles of 115 independent breast tumor samples and
categorized breast tumors into five groups: luminal A [estrogen
receptor (ER)]; luminal B (ER); HER2 overexpressing; nor-
mal breast-like; and basal-like. On the basis of 300 tumors
with expression profiles and associated clinical follow-up data
spanning three independent data sets, breast cancers of the
basal-like subtype comprised 19% of the tumors and had poor
prognoses as assessed by relapse-free survival (2–4). Therapies
targeting the ER or HER2 oncogene would not be expected to be
effective on basal-like breast cancers because this subtype typ-
ically expresses neither of these proteins. Although diagnostic
antibodies that work in formalin-fixed, paraffin-embedded ar-
chival tissue do not exist for most genes present in the basal-like
breast cancer gene expression profile, commercial antibodies to
cytokeratin 5/6 and cytokeratin 17 are available. The prevalence
and poor prognosis of basal-like breast cancers has been vali-
dated immunohistochemically on a 564 case tissue microarray
(TMA) with 66-month mean outcome data using overall sur-
vival as an end point (5); 16% of tumors in this cohort stained
positive for cytokeratin 5/6 and/or cytokeratin 17.
Recently, another independent TMA study of basal cyto-
keratin expression and related immunohistochemical markers
was published (6). In this study, breast cancers that were cyto-
keratin 5/6 positive were found to be associated with expression
of the epidermal growth factor receptor (HER1), with the
proliferation marker Ki-67, with accumulation of p53 and
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with increased cytogenetic abnormalities. In another recent
study, the basal-like subtype, as defined by cytokeratin 5/6
expression by immunohistochemistry (IHC), was also found to
be common among breast cancer patients with hereditary
BRCA1 mutations (7).
Basal-like breast cancers represent a poorly characterized
subtype of tumor with no validated clinical assay to identify
them; therefore, in this report, we first improved our immuno-
histochemical definition of basal-like breast cancers by compar-
ison to our gene expression data. Next, based on a larger cohort
of breast cancer patients with longer follow-up, we show that the
basal-like breast cancer tumors show poor disease-specific sur-
vival times and show that HER1 expression is a marker that
helps to distinguish basal-like breast cancers. These data iden-
tify a simple set of IHC markers that can be routinely used in the
clinical setting to accurately identify basal-like breast cancers.
MATERIALS AND METHODS
DNA Microarrays. The microarray data from Sørlie et
al. (2) were used to identify genes/proteins whose pattern of
expression could assist in identifying basal-like breast cancers
using IHC. These data encompassed expression values for 8700
genes obtained from 115 grossly dissected tumors and also
contained associated clinical information. Three additional
basal-like breast cancers were identified at University of North
Carolina at Chapel Hill using microarray analysis; total RNA
from these tumors was isolated using a Qiagen RNeasy Midi kit
according to the manufacturer’s protocol (Qiagen, Valencia,
CA). Next, we performed microarray analysis by first labeling
the samples using an Agilent Low Input Linear Amplification
kit (Agilent Technologies, Palo Alto, CA) and 2 g of starting
total RNA. These experiments used Agilent Human A1 oligo
microarrays. The tumor samples were labeled with Cy5 and
were compared with a common reference sample that was
composed of the Stratagene Universal Human Reference sample
that was augmented with a 1/10 amount of RNA from the MCF7
cell line and a 1/10 amount of RNA from the immortal human
mammary epithelial cell line ME16C (8). The microarrays were
scanned on an Axon 4000B Scanner with image analysis ac-
complished using GenePix Pro 4.0. The raw data (.gpr files)
tables were uploaded into the University of North Carolina
Microarray Database, which is a mirror of the Stanford Microar-
ray Database (9). A global, linear normalization was performed
to adjust the Cy3 and Cy5 channels (9). The three new microar-
ray raw data tables are available at the University of North
Carolina Microarray Database11 and have been deposited into
the Gene Expression Omnibus under the accession numbers
GSM21709, GSM21710, and GSM21711.
TMAs. Cases for this study were drawn from 2475 pa-
tients participating in British Columbia Cancer Agency trials
conducted between the late 1970s and 1990, involving stage
I–III breast cancer (10–13). Cases for the microarray were
selected based on the availability of paraffin blocks and repre-
sent a subset of patients in each trial. Paraffin blocks of forma-
lin-fixed tissue were available for 930 patients. All patients have
information on the date of diagnosis, age at diagnosis, date and
type of relapse, and (in all but five cases) date and cause of
death; most patients also have complete information on tumor
size and histology as well as nodal status (14). The study was
approved by the Clinical Research Ethics Board of the Univer-
sity of British Columbia. Patients have been followed regularly,
with the last update in 2001 (mean and median follow-up from
original diagnosis until analysis for patients still alive at time of
analysis is 17.4 years; range, 9.8–28.1 years).
The TMA was constructed by extracting 600-m diameter
cores of histologically confirmed invasive breast carcinoma
from the original paraffin blocks using a Beecher Instruments
tissue core extractor and re-embedding these cores into a grid-
ded paraffin block. Three such recipient blocks were con-
structed, containing 333, 334, and 336 tissue cores each ar-
ranged in four 12 7 sectors (15, 16). Control tissue cores from
benign breast and kidney were included in each of these paraffin
blocks. Single cores were taken from the original biopsy tissue
from each of 930 patients. Forty-two additional cores were
available from patients who had additional surgeries. After
construction, 4-m tissue sections were cut and adhered to
Fisher SuperFrost Plus glass slides.
IHC and Scoring. Each set of three glass slides com-
prising the TMA was stained with commercially available an-
tibodies: ER (Ventana, Tucson, AZ) antibody was used at 1:50
dilution, with a 4-min microwave antigen retrieval in citrate
buffer. Cytokeratin 5/6 (Boehringer Mannheim, Indianapolis,
IN) and cytokeratin 17 (DAKO, Carpinteria, CA) antibodies
were both used at 1:10 dilution with antigen retrieval by pro-
teinase K and microwave as above. c-KIT (also known as
CD117 and as SCFR) antibody A4502 (DAKO) was used at
1:200 dilution with antigen retrieval by 40 min of steam treat-
ment in EDTA buffer. HER1 and HER2 were stained using the
PharmDX and Herceptest kits, respectively, according to man-
ufacturer’s instructions (DAKO). Detection was by EnVision
(DAKO) with diaminobenzidine chromogen as per routine pro-
tocol. Five-m whole tissue sections from 21 surgical cases
selected because of their basal-like gene expression profile were
treated similarly. ER status for the 115 samples used in the
expression profiling studies of Sørlie et al. (2) was previously
published and based on a ligand binding assay. For the 18
basal-like breast cancers examined here from that study, we also
performed IHC for ER.
Staining results were assessed by at least two pathologists,
using a three-point scoring system, where 0  invasive tumor
cells present in the tissue core and no staining seen, 1 invasive
tumor cells present with weak staining intensity and/or20% of
tumor cells stained, and 2  invasive tumor cells present with
strong staining in20% of tumor cells. A positive ER stain was
recorded only if immunostaining was seen within the nuclei of
invasive carcinoma cells, whereas positive HER2 required
strong membranous staining. Cytokeratin 5/6, cytokeratin 17,
and HER1 were scored positive if any (weak or strong) cyto-
plasmic and/or membranous invasive carcinoma cell staining
was observed. c-KIT immunostaining with polyclonal antibody
A4502 had a higher degree of nonspecific background than the
other antibodies used and was interpreted such that a score of 1
required 25–75% of cells positive and 2 required 75% cells11 Internet address: https://genome.unc.edu/.
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strongly positive for cytoplasmic and/or membranous staining.
Tissue cores that failed to adhere to the glass slide, did not
contain invasive carcinoma, had been cut through, or were
otherwise uninterpretable were excluded, with the numbers of
informative cases for each marker shown in Table 1. Primary
immunostained slide image data for ER, HER2, cytokeratin 5/6,
cytokeratin 17, c-KIT, and HER1 were digitally acquired using
a Bacus Laboratories, Inc., Slide Scanner system (Lombard, IL),
and these images (5000) are available online.12
Statistical Analysis. Results were tabulated into a Mi-
crosoft Excel worksheet format using the TMA-Deconvoluter
program (17) and exported into the SPSS 11.0 statistical suite.
For data analysis, immunostained cores scored as either 1 or 2
were considered positive, except in the case of HER2, where a
score of 2 was required to be considered positive (equivalent to
strong 3 staining when using the Herceptest). Kaplan-Meier
survival analyses were carried out for both overall and breast
cancer disease-specific survival, using the Breslow test for dif-
ferences between groups (18), where the proportional hazards
assumption was not violated by crossing hazard function curves;
log-rank statistics were also calculated. Prognostic variables
were analyzed using univariate analysis, paired analysis, and
jointly by stepwise as well as by overall regressions. Multiva-
riate analyses was performed where the proportional hazards
assumption was not violated, using a Cox regression model.
Results were considered statistically significant when P from a
two-tailed test was 0.05. Hierarchical clustering of TMA
immunostaining results was performed as described in Nielsen
et al. (19), with filters set to 70% interpretable staining data/
core.
RESULTS
Comparison of cDNA Microarray and IHC Patterns in
Basal-Like Tumors. Our gene expression profiling data di-
vided breast carcinomas into five subtypes: luminal A and B
tumors (both clinically ER); HER2 positive; normal breast-
like; and basal-like (1, 2, 20). A goal of this study was to
develop a clinically applicable assay to identify breast basal-like
cancers. Therefore, we first performed a review of our gene
expression data for basal-like breast cancers from Sørlie et al.
(2) to determine what genes/proteins might be exploitable for
the clinical categorization of these tumors. Our analysis of the
115 tumors from Sørlie et al. (2) revealed that the basal-like
breast cancers as a group (19 of 115) showed high expression
levels for cytokeratin 5, HER1, and c-KIT and had low to absent
gene expression of ER and HER2 (Fig. 1A). To determine
whether this finding could be used to identify basal-like breast
cancers, we asked if patients were first selected to be ER and
HER2, which we define as a tumor that was not HER2 3 by
IHC and was10 fmol/mg using a ligand-binding assay for ER,
then how many of these patients had basal-like breast cancers.
Of the 115 tumors assayed in Sørlie et al. (2) by microarray, 72
had clinical data for ER and HER2; from these 72 tumors, 18
were clinically ER and HER2. Starting with these 18 ER/
HER2 tumors, we determined that 15 were basal-like breast
cancers by microarray analysis, suggesting that the majority
(15 of 18) of clinically determined ER/HER2 tumors were
basal-like breast cancers.
A second way to characterize the basal-like subtype is to
identify these tumors using microarray analysis and then deter-
mine which IHC patterns correlate with this expression profile.
As shown in Fig. 1A, in the 115 tumors taken from Sørlie et al.
(2), the basal-like breast cancers (red dendrogram branch)
showed high expression of cytokeratin 5 and also tended to
show high expression of HER1 and/or c-KIT. To corroborate
these mRNA findings, we obtained paraffin sections from 18 of
the basal-like tumors from Sørlie et al. (2), and from 3 more
basal-like breast cancers from our current microarray studies,
which were identified using the breast intrinsic gene list and
hierarchical clustering analysis, giving us 21 tumors that were
basal-like breast cancers as defined by DNA microarray analy-
sis. We next performed IHC on these 21 tumors and other breast
tumors for cytokeratin 5/6, HER1, c-KIT, ER, and HER2 (Fig.
1B). Examples of immunostaining for cytokeratin 5/6 and HER1
on some of the basal-like tumors and a normal breast sample are
presented in Fig. 1C. Cases positive for ER showed the charac-
teristic nuclear staining pattern (data not shown), whereas cy-
tokeratin 5/6-positive cases showed a cytosolic and often focal
pattern in tumors; in normal breast, cytokeratin 5/6 staining has
been shown to display a wide variety of staining patterns from
identifying the myoepithelial cell layer to identifying a layer of
cells that line the ducts and that may represent committed stem
cells (21). HER2-positive cases showed a membranous pattern
(data not shown), whereas HER1 (Fig. 1C) and c-KIT-positive
tumors showed a mixed cell membranous and cytoplasmic pat-
tern; nuclear/nuclear membranous staining was not seen. In
normal breast, c-KIT staining was present in most epithelial
cells, whereas HER1 staining was largely restricted to the stro-
mal cell side of the basal/myoepithelial cell layer (Fig. 1C).
Using these IHC reagents, we determined that 13 of 21
basal-like breast cancers were cytokeratin 5/6 positive, 12 of 21
were HER1 positive, and 6 of 21 were c-KIT positive (Fig. 1B)
when we scored both weak positive and strong positive cases as
positive. These data suggest that an IHC surrogate for gene array
experiments to identify basal-like breast cancers is to select for
cases that are ER-negative, HER2-negative-low, and cytokeratin
5/6 and/or HER1. All 16 tumors with this immunohisto-
chemical profile had the basal-like gene expression profile (Fig.
1). In total, 21 tumors were basal-like by DNA microarray,
meaning the IHC surrogate definition is 76% sensitive and
100% specific. An alternative to this assay that some are using
12 Internet address: http://microarray-pubs.stanford.edu/tma_portal/her1/
index.shtml.









ER 755 302 (40) 453 (60)
HER2 744 150 (20) 594 (80)
CK5/6 788 110 (14) 678 (86)
CK17 765 35 (5) 730 (95)
HER1 614 82 (13) 532 (87)
c-KIT 761 105 (14) 656 (86)
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to identify basal-like breast cancers is to select for ER-negative
and HER2-negative-low tumors; however, for technical reasons,
it can be dangerous to base an assay upon the absence of all
staining.
Association of Basal Cytokeratins with Poor Clinical
Outcome. We previously demonstrated that expression of ba-
sal cytokeratin markers by IHC in breast carcinomas (cytokera-
tin 5/6 and/or cytokeratin 17) predicted poor outcomes (5).
Fig. 1 Gene expression patterns in basal-like tumors and their correlation with immunohistochemistry. A, the 115 patient/tumor sample dendrogram
was taken from the hierarchical clustering analysis presented in Sorlie et al. (2); the tumors were grouped using the breast intrinsic gene list based
on 45 paired samples. The basal-like breast cancers are identified in red. The gene expression data for ER, HER2, c-KIT, cytokeratin (CK)5, and
HER1 are shown with red squares representing the highest average expression, black representing average gene expression, and green representing
the lowest below average. B, 21 basal-like breast cancers identified by gene expression profiling were tested and scored by IHC for CK5/6, HER1,
c-KIT, ER, and HER2 (0  negative, 1  weak and/or focal staining, 2  strong diffuse staining), except for HER2, which was scored using a
standard (0–3) scale. ND  not determined. C, representative immunostaining results for four basal-like tumors and a normal breast sample for
CK5/6 and HER1.
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To corroborate these data, we used a different patient cohort
TMA containing 930 cases with a median follow-up time of
17.4 years. The overall frequency of staining observed for each
of the immunohistochemical markers over the interpretable
cases is presented in Table 1. Kaplan-Meier survival analysis of
cases with an interpretable score for cytokeratin 5/6 and/or
cytokeratin 17 (n 829) shows that positivity for either of these
basal markers correlates with shorter disease-specific survival
than for negative cases (Fig. 2A; median survival 8.8 versus 13.2
years, P  0.015). From this set of patients, nodal status was
available for 682, of whom 472 were positive and 210 negative
for lymph node metastasis. In the lymph node-positive group,
the presence of either basal cytokeratin was associated with a
significantly poorer outcome (Fig. 2B; P  0.008 by Breslow
test); in the lymph node-negative group, a trend was seen but did
not reach statistical significance (Fig. 2C). These data confirm
our earlier finding (Ref. 5 and see “Discussion”); however,
because the staining pattern of cytokeratin 17 is often difficult to
score, we sought to improve upon this classification.
Association of the Basal-Like Subtype with HER1 and
c-KIT Expression. Part of our new basal-like breast cancers
immunoprofile was expression of HER1. On the current 930
case TMA series, HER1 expression was present in 44.1% (41 of
93) of the cancers that were positive for a basal cytokeratin,
which was similar to the percentage seen on the DNA microar-
ray cohort described above (12 of 21 57%). HER1 expression
was significantly less common among the basal cytokeratin-
negative cases (41 of 521  7.9%, P  0.001 by Fisher’s exact
test) and was present in only 2.0% (5 of 254) of ER-positive
cases. HER1 was demonstrable in a much larger fraction (82 of
614  13.4%) of breast cancers than cytokeratin 17 (35 of
765  4.6%), suggesting that inclusion of HER1 into the IHC
definition of basal-like tumors might be more valuable than
cytokeratin 17. By comparison, cytokeratin 5/6 immunostaining
was positive in 110 of 788 14.0% of the breast cancers tested.
In a univariate analysis, HER1 expression was associated with
poor survival (median, 5.7 versus 13.4 years; P  0.01 by
log-rank and Breslow) as shown in Fig. 2D. In multivariate
analysis, expression of HER1 was a significant independent
negative prognostic factor (P  0.017, relative risk 1.54) when
fitting the available clinical variables of nodal status (relative
risk 2.10) and tumor size (relative risk 1.12) in a Cox propor-
tional hazards model. Histological grade could not be used in
this multivariate analysis because accurate grading information
was unavailable for the majority of cases.
c-KIT expression was present in 14% (105/761) of all
breast cancers when strong and weak staining intensities were
both considered positive. 31% (32/102) of the cancers positive
for basal cytokeratins were also positive for c-KIT, whereas
only 11% (67/605) of basal cytokeratin negative cases were
positive (P  0.001 by Fisher’s exact test); in addition, we
determined by IHC that 6 of 21 basal-like breast cancers from
the microarray studies were also c-KIT positive (Fig. 1). When
only strong c-KIT staining was considered, only 2.2% (17 of
761) of the tumors were positive. This is precisely the frequency
obtained by Simon et al. (22), who determined that 43 of 1654
patients in their breast tumor TMA study expressed c-KIT;
Simon et al. (22) also showed that none of these tumors con-
tained mutated c-KIT. By mRNA expression, c-KIT is one of
the best basal-specific markers; however, by IHC, many of the
Fig. 2 Kaplan-Meier survival
curves based on basal cytokera-
tin and HER1 staining. A,
Kaplan-Meier disease-specific
survival (DSS) curve for 829 tu-
mors assessed for cytokeratin
(CK)5/6 and CK17. B, Kaplan-
Meier DSS curve for 472 lymph
node-positive breast cancers as-
sessed for cytokeratin 5/6 and
cytokeratin 17. C, Kaplan-Meier
DSS curve for 210 lymph node-
negative breast cancers assessed
for CK5/6 and CK17. D,
Kaplan-Meier DSS curve in 609
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tumors that showed c-KIT mRNA were not positive for c-KIT
protein expression. In contrast to HER1, c-KIT was not associ-
ated with significant differences in patient outcome on our TMA
cohort regardless of whether positivity was called only for
strong immunostaining, or for strong and weak combined (data
not shown).
Refinement of an IHC Definition for Basal-Like Tu-
mors. Given the association of HER1 with the basal subtype,
its prognostic significance in univariate analysis and its greater
sensitivity when compared with cytokeratin 17, we sought to
incorporate this marker into an immunohistochemical definition
of basal-like breast cancers. A total of 663 TMA core samples
had sufficient interpretable staining results to allow sample
characterization into one of four groups (Table 2). These cate-
gories were defined in a clinically practical way: (a) if a tumor
is HER2 positive (i.e., 3 by IHC), it falls immediately into
group H; (b) if a tumor is HER2 negative-low and ER positive,
then it is group E; (c) if a tumor is both HER2 and ER negative
but positive for at least one basal-enriched marker (cytokeratin
5/6 and/or HER1), then that tumor falls into group B; and (d) if
a tumor is negative for all four markers, it falls into group N
(undetermined). Using this definition, the basal-like breast can-
cers (group B) comprised 15% (102 of 663) of the tumors
studied. Fig. 3 shows a hierarchical cluster diagram of the TMA
results for the six protein markers and shows the correlation in
expression among the basal-like breast cancer-enriched markers
cytokeratin 5/6, cytokeratin 17, HER1, and c-KIT. A version of
this cluster diagram exists on our web site;12 at this web site,
digital images are available for all tissue cores by clicking on the
StainFinder field next to each individual tumor.
Basal-like breast cancers, defined immunohistochemi-
cally as ER negative, HER2 negative, and cytokeratin 5/6
and/or HER1 positive, not only correlated best with the
basal-like breast cancers gene expression profile but also
gave the most significant survival differences on TMA (Fig.
4) with a much worse prognosis than for group E (ER).
Outcomes were similar to those of the HER2/group H; of
note, these data were collected before the use of trastuzumab
therapy for HER2 tumors. These results agree with the
clinical outcomes of basal-like breast cancers in the Norway/
Stanford and Dutch breast tumor expression profiling studies
(1–3), which further validates the clinical significance of the
basal-like breast cancers in a fashion that can be applied to
standard formalin-fixed, paraffin-embedded tissue. Tumors
negative for all markers (group N) also fared poorly and
probably include tumors that represent a number of different
subtypes; likely included in this uncategorized group are a
few basal-like breast cancers not detected by cytokeratin 5/6
or HER1 because of their imperfect sensitivity and some-
Fig. 3 Hierarchical cluster analysis of breast carcinoma TMA immu-
nostaining results. The six markers evaluated in this study [ER, HER1,
HER2, c-KIT, cytokeratin (CK)5/6, and CK17] were scored and used in
a clustering analysis where each row represents a different tumor, and
each column represents a different IHC stain. The analysis shows that
the basal-like markers stained similar cases, as indicated by the very
short dendrogram branches linking these markers. A more detailed
version of this figure, linked to the primary TMA image files, is
available online.12
Table 2 Frequencies of the immunohistochemically defined subtypes of breast cancers in 663 carcinoma cases informative for the tested
markers using tissue microarrays
Group HER2 ER Cytokeratin 5/6 and/or HER1 Frequency (%)
H (HER2) Positive Any Any 150 (23)
E (luminal) Negative Positive Any 263 (40)
B (basal-like) Negative Negative One or both positive 102 (15)
N (negative) Negative Negative Negative 148 (22)
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times focal expression pattern, luminal-derived tumors that
very weakly express ER, normal breast-like tumors, and
tumors put into this category due technical failures. Because
of the heterogeneity within the all-negative group, at least
one positive marker is needed to assure high specificity, and
it is for this reason that our assay includes cytokeratin 5/6
and/or HER1 positivity. Finally, the basal-like breast cancers
that were HER1 positive but cytokeratin 5/6 negative could
differ in outcomes from their counterparts who were HER1
negative and cytokeratin 5/6 positive. However, the HER1-
positive only basal-like breast cancers and the cytokeratin
5/6-positive only basal-like breast cancers showed equally
poor outcomes, both with statistical significance in a univa-
riate analysis (data not shown).
DISCUSSION
Building upon our gene expression studies (1, 2, 20), van
de Rijn et al. (5) found that expression of the basal-like breast
cancers markers cytokeratin 5/6 and cytokeratin 17 predicted
poor outcome in breast tumor patients. Using a similar approach
here, our current TMA study was able to again validate the
clinical importance of the basal-like breast cancers subtype. The
current and larger series allowed confirmation of the frequency
(15%) of this subtype on an independent cohort and found a
clear association with short disease-specific survival, as was
also seen in other studies (2, 23). We did identify one difference
in outcomes between our two TMA studies, which was that in
the van de Rijn et al. (5) study, the cytokeratin 5/6 and/or
cytokeratin 17-positive tumors were significant predictors of
outcome in the node-negative subset, whereas in this study, the
cytokeratin 5/6- and/or cytokeratin 17-positive tumors were a
significant predictor in the node-positive group; we believe this
finding may be due to the different patient cohorts and are
examining this point on additional cohorts.
Bocker et al. (24) and Korsching et al. (6) have hypothe-
sized that a basal-like stem cell, characterized by its preferential
expression of cytokeratin 5/6 and low expression of luminal
cytokeratins (cytokeratin 8/18), might represent a breast cancer
subclass. Wetzels et al. (25) found a strong correlation between
basal cytokeratin expression and cell proliferation, which was
corroborated by our profiling studies (1, 20, 26). However, the
staining pattern of the basal keratins (cytokeratin 5/6 and espe-
cially cytokeratin 17) is challenging to detect by immunohisto-
chemical methods because of focal and often weak reactivity.
On the basis of a review of our gene expression data followed by
immunohistochemical validation, we found that we can better
define the basal-like breast cancers by identifying those tumors
that are negative for both ER and HER2 and that are positive for
cytokeratin 5/6 and/or HER1. The HER1 marker is much easier
to score than cytokeratin 5/6 and is much more frequent than
cytokeratin 17. Also, the use of a single basal marker (cyto-
keratin 5/6), whereas successful in identifying a subset of pa-
tients with poor outcomes, misses approximately half of basal-
like tumors. In addition, reliance on the lack of staining for ER
and HER2 alone to identify basal-like breast cancers risks
misassignment based on technical failures and/or biological
heterogeneity.
HER1 expression is not a basal-like breast cancer-specific
marker like cytokeratin 5/6; however, it was expressed in
enough basal-like breast cancers that when combined with other
markers, it greatly assists in their immunohistochemical identi-
fication. More importantly, HER1 is also a target for several
recently developed drugs, including therapeutic antibodies
(cetuximab) and small molecule tyrosine kinase inhibitors (ge-
fitinib, erlotinib; Refs. 27, 28). The evaluation of HER1 inhib-
itors as a monotherapy in unselected breast cancer patients has
begun; however, the association of HER1 expression with basal-
like breast cancers could define a subset of breast cancer pa-
tients who might benefit from treatment with one of these
agents, either alone, or in combination with standard chemo-
therapy. Our results also show a relationship between c-KIT
expression and the basal-like breast cancer subtype, with the
majority of c-KIT-positive breast tumors belonging to the basal-
like breast cancer subtype. Here, we show that a simple panel of
four antibodies can robustly identify basal-like breast cancers
using standard IHC, which could serve as the basis to identify
basal-like breast cancer patients in the clinical setting and for the
retrospective evaluation of the efficacy of known chemothera-
peutic agents on this tumor subtype.
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